&lt;i&gt;Listeria monocytogenes&lt;/i&gt; Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma

Ueno, Tomoko; Ohta, Takanori; Imanaga, Hiroshi; Nakazawa, Megumi; Sato, Yoriko; Sugio, Yasuhiro; Uchida, Yukiko; Ohno, Yuju; Uehara, Yasufumi

doi:10.2169/internalmedicine.7509-21

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 disseminated cryptococcosis are reported. [43][44][45][46][47][48][49][50] As expected, infections occur at a higher rate in those patients with higher grade neutropenia and lymphopenia, notably heavily pretreated patients treated with combination regimens within the initial 6 months of treatment. In this population treated with daratumumab, the median time to severe infection was ~50 days in patients with severe lymphopenia versus ~90 days in those without severe lymphopenia.…”

Section: Fda-approved Next-generation Therapeuticssupporting

confidence: 55%

“… 42 Atypical infections are uncommon, however, reactivation of herpes zoster and Epstein–Barr virus/cytomegalovirus, pneumocystis jirovecii pneumonia (PJP), progressive multifocal leukoencephalopathy, bronchopulmonary aspergillosis, fungal meningitis, listeriosis, and disseminated cryptococcosis are reported. 43 – 50 As expected, infections occur at a higher rate in those patients with higher grade neutropenia and lymphopenia, notably heavily pretreated patients treated with combination regimens within the initial 6 months of treatment. In this population treated with daratumumab, the median time to severe infection was ~50 days in patients with severe lymphopenia versus ~90 days in those without severe lymphopenia.…”

Section: Fda-approved Next-generation Therapeuticsmentioning

confidence: 57%

See 1 more Smart Citation

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

Steinbach

Julian

McClune

et al. 2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

The therapeutic options available for patients with multiple myeloma have greatly expanded over the past decade and incorporating these novel agents into routine clinical practice has significantly improved outcomes. The next generation of therapeutics is available for relapsed and refractory patients either as standard of care or in clinical trial, and these drugs represent a generational paradigm shift. Patients now have access to a multitude of novel immunotherapeutics, including monoclonal antibodies, an antibody–drug conjugate, chimeric antigen receptor T-cells (CAR-T), and bispecific T-cell redirecting antibodies, and novel oral therapies including selinexor (selective inhibitor of nuclear export) and venetoclax (bcl-2 inhibitor). While these drugs have the potential to be highly efficacious in certain subsets of patients when used as single agents or in combination regimens, they are each associated with unique toxicity profiles. It is imperative to understand these potential adverse events to ensure patient safety. Appropriate supportive care management is paramount to maximize drug exposure and therapeutic efficacy. The following review focuses its discussion on drugs and combination regimens that are currently FDA-approved and those that continue to be investigated in clinical trials, highlights the clinically relevant toxicity profiles for each of the different agents, and provides practical considerations for the treatment team.

show abstract

Section: Fda-approved Next-generation Therapeuticssupporting

confidence: 55%

Section: Fda-approved Next-generation Therapeuticsmentioning

confidence: 57%

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

Steinbach

Julian

McClune

et al. 2022

Therapeutic Advances in Hematology

View full text Add to dashboard Cite

show abstract

“…The first patient reported to have listeria infection complicating targeted therapy was a patient with Crohn's disease on infliximab, an anti-TNFα monoclonal antibody (5). Since then, including the two cases in the present cohort, a total of 82 cases of listeriosis complicating targeted therapy have been reported in the scientific literature (45)(46)(47)(48)(49)(50)(51)(52)(53)(54)(55)(56)(57). For 69 out of the 82 patients, gender, age, and clinical information were reported (5-11, 13-26, 28-32, 34-37, 45-57).…”

Section: Discussionmentioning

confidence: 86%

Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?

Xing

Lau

et al. 2022

Front. Med.

View full text Add to dashboard Cite

Targeted therapies are widely used for treatment of autoimmune diseases as well as solid organ and hematological malignancies. Various opportunistic infections have been described in patients on targeted therapies. Although case reports or a few case series of listeriosis have been reported to be associated with targeted therapy, most of the cases were related to anti-tumor necrosis factor-α monoclonal antibody. In this study, we describe the epidemiological and clinical profiles of listeriosis in a tertiary hospital in Shenzhen, a Southern Chinese metropolitan city in China. During the 9-year-and-6-month study period, a total of five cases of listeriosis were recorded and all of them had Listeria monocytogenes bacteremia. All five patients had predisposing factors, including corticosteroid (n = 3), targeted therapy (n = 2), pregnancy (n = 2) and anti-interferon gamma autoantibody (n = 1). The two patients who had targeted therapy during their course of cancer treatment received inhibitors of the epidermal growth factor receptor (EGFR)/human epidermal growth factor receptor 2 (HER2) pathway. The first one was a 52-year-old woman with metastatic adenocarcinoma of the lung. She was given gefitinib (EGFR tyrosine kinase inhibitor), osimertinib (third-generation EGFR tyrosine kinase inhibitor) and afatinib (tyrosine kinase inhibitor that can bind to EGFR, HER2 and HER4). The second one was a 40-year-old woman with carcinoma of the breast with brain metastasis. She was given trastuzumab (anti-HER2 monoclonal antibody) and lapatinib (dual tyrosine kinase inhibitor of the EGFR/HER2 pathway). These two patients represent the second and third reports of listeria infections associated with EGFR/HER2 pathway inhibitors in the literature. Targeted therapy is an important predisposing factor for listeriosis. Listeria infection is an important differential diagnosis in patients on targeted therapy who present with sepsis and/or central nervous system infection, and the use of antibiotic regimens that cover listeria is crucial for empirical treatment. Avoidance of high-risk food items in these patients is important for the prevention of listeriosis.

show abstract

“…A facultative anaerobe and a gram-positive pathogenic bacterium, Listeria monocytogenes (L. monocytogenes) is the causative organism of listeriosis 1 . Listeriosis is a foodborne infection and is associated with food items such as meat and dairy products 2 . Infections caused by Listeria monocytogenes can present in human beings as bacteremia and Meningoencephalitis in patients who are immunocompromised and in older patients.…”

Section: Introductionmentioning

confidence: 99%

Listeria Monocytogenes, a Case of Mistaken Identity

Dogar,

Danish Iqbal,

Abdul Ahad

et al. 2022

Pak Postgrad Med J.

View full text Add to dashboard Cite

A 74 years old female patient who was a known case of Diabetes Mellitus, Hypertension, and Breast Cancer presented in the Accident and Emergency Department with complaints of fever, seizures, and an altered state of consciousness. The patient was febrile with a temperature of 40° C, blood pressure was 140/80 mmHg, and pulse was 90 beats/min. She was in an altered state of consciousness with a Glasgow Coma Scale score of 10/15. The rest of the physical examination was unremarkable. The pleomorphic nature of this bacterium and clinical presentation similar to meningitis caused by other micro-organisms make the laboratory and clinical diagnosis respectively rather difficult. We illustrate the clinical presentation, antibiotic therapy, and laboratory diagnosis of L.monocytogenes in a patient with weak immune status. A high clinical suspicion of Listeriosis is essential for prompt and accurate treatment if a case of meningitis is not responding to traditional empirical antibiotics, and especially in immunocompromised.

show abstract

<i>Listeria monocytogenes</i> Bacteremia During Isatuximab Therapy in a Patient with Multiple Myeloma

Cited by 4 publications

References 10 publications

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

Toxicity management strategies for next-generation novel therapeutics in multiple myeloma

Listeriosis in a Metropolitan Hospital: Is Targeted Therapy a Risk Factor for Infection?

Listeria Monocytogenes, a Case of Mistaken Identity

Contact Info

Product

Resources

About